翻訳と辞書 ・ LY-215,840
・ LY-2183240
・ LY-235,959
・ LY-255582
・ LY-272,015
・ LY-293284
・ LY-2940094
・ LY-307,452
・ LY-310762
・ LY-320,135
・ LY-334370
・ LY-341,495
・ LY-344,545
・ LY-367,265
・ LY-379,268
・ LY-404,039
・ LY-404,187
・ LY-487,379
・ LY-503,430
・ LY-60 / FD-60 / PL10
・ Ly-Cilph
・ Ly-Fontaine
・ LY2181308
・ LY294002
・ LY6
・ LY6E
・ LY6G6E
・ LY75
・ LY9
・ Lya
|
|
LY-404,039
LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. Pharmacological research has focused on its potential antipsychotic and anxiolytic effects. LY-404,039 is intended as a treatment for schizophrenia and other psychotic and anxiety disorders by modulating glutamatergic activity and reducing presynaptic release of glutamate at synapses in limbic and forebrain areas relevant to these disorders. Human studies investigating therapeutic use of LY-404,039 have focused on the prodrug LY-2140023, a methionine amide of LY-404,039 (also called pomaglumetad methionil or LY-2140023 monohydrate) since LY-404,039 exhibits low oral absorption and bioavailability in humans.〔
Early human trials using this prodrug form of LY-404,039 gave encouraging results.〔 However, pharmaceutical company Eli Lilly terminated further development of the compound in 2012 after it failed in phase II clinical trials.〔(Strike three: Bad data bury Eli Lilly's late-stage schizophrenia drug )〕〔(– Treatment of Schizophrenia )〕 In September 2013, the results of a randomized, placebo-controlled clinical trial investigating the impact of adjunctive LY-2140023 on prominent negative symptoms in schizophrenia was published and failed to demonstrate any benefit.
==Pharmacology==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「LY-404,039」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|